Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases

Abstract

We conducted a single institution phase II trial to evaluate the tolerability and effectiveness of therapy with arsenic trioxide (ATO) and ascorbic acid (AA) with temozolomide (TMZ) in patients with advanced melanoma. Planned enrollment was for 40 patients. Eligible patients were required to have metastatic melanoma with or without brain metastases, an ECOG performance status of 0-2, and adequate organ function. The primary endpoints were overall response rate and degree of grade 4 toxicity. ATO was administered as a loading dose at 0.25 mg/kg/day for 5 days during week 0, and then twice weekly at 0.35 mg/kg during an 8-week cycle. Each infusion of ATO was followed by an infusion of 1000 mg of AA. TMZ was given at the standard dose of 200 mg/m for 5 days during weeks 1 and 5 of each cycle. Eleven patients were enrolled with 10 evaluable for response, five with central nervous system disease. No responses were seen among the first 10 patients and on the basis of a predetermined stopping rule, the trial was terminated. Common grade 1 and 2 side effects included nausea and vomiting (10), fatigue (six), edema (six), rash (six), and elevated AST or ALT (six). Grade 3 and 4 side effects included nausea and vomiting (three), elevated AST or ALT (two), seizure (one), and renal failure (one). This is the first trial combining ATO with chemotherapy in a solid tumor. ATO and AA were administered in the outpatient setting with TMZ in 11 patients with an acceptable side effect profile. No responses were seen in the first 10 evaluable patients leading to early closure of the study. Further studies using ATO and AA with TMZ with this dosing schedule in advanced melanoma are not warranted.

Rational Incorporation of Selenium into Temozolomide Elicits Superior Antitumor Activity Associated with Both Apoptotic and Autophagic Cell Death

“…This chemotherapeutic agent is also utilized for treating patients with metastatic melanoma; in particular, due to its ability to penetrate through the blood-brain barrier, TMZ is often prescribed to patients with brain metastases of melanoma [1]. This drug exerts its antitumor activity by interfering with DNA replication.…”

Vitamin C: Overview and Update

“…[77][78][79] Recently, several small uncontrolled trials have examined the efficacy of intravenous vitamin C as cancer therapy with mixed results. [80][81][82] However, the observation that patient well-being and quality of life assessments were improved with vitamin C infusions is encouraging. 83 Intravenous vitamin C is widely used by complementary and alternative medicine practitioners for a variety of conditions including infection and fatigue.…”

Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities

“…Clinical development of As 2 O 3 for oncological applications beyond APL is ongoing. In recently completed Phase II trials, As 2 O 3 did not offer therapeutic benefit in patients with adenocarcinoma of the pancreas or patients with metastatic melanoma (17), but promising results were obtained in a Phase I=II study of As 2 O 3 =bortezomib= L-ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma (27). 2.…”